Lapatinib and breast cancer: current indications and outlook for the future

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J. Clin.59, 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells15, 1–8 (1997).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244, 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur. J. Cancer43, 481–489 (2007).
   PubMed Web of Science ®Google Scholar
• Burstein HJ. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med.353, 1652–1654 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235, 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J. Clin. Oncol.27, 5700–5706 (2009).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353, 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp. Cell Res.316, 1083–1100 (2010).
   PubMed Web of Science ®Google Scholar
• Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol.3, 269–280 (2006).
   PubMedGoogle Scholar
• Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene22, 6570–6578 (2003).
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast15, 219–225 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou Y, Li S, Hu YP et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res.66, 404–411 (2006).
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Dhadda AS, Shehata M, Chan S. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. Expert Opin. Pharmacother.8, 2189–2204 (2007).
   PubMed Web of Science ®Google Scholar
• Tomasello G, Bedard PL, de Azambuja E, Lossignol D, Devriendt D, Piccart-Gebhart MJ. Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib. Crit. Rev. Oncol. Hematol.75(2), 110–121 (2010).
   PubMedGoogle Scholar
• Burris HA III, Taylor CW, Jones SF et al. A Phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin. Cancer Res.15, 6702–6708 (2009).
   PubMed Web of Science ®Google Scholar
• Koch KM, Reddy NJ, Cohen RB et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J. Clin. Oncol.27, 1191–1196 (2009).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J. Clin. Oncol.25, 3397–3398 (2007).
   PubMed Web of Science ®Google Scholar
• Burris HA III, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol.23, 5305–5313 (2005).
   PubMed Web of Science ®Google Scholar
• Gomez HL, Doval DC, Chavez MA et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol.26, 2999–3005 (2008).
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Storniolo AM, Franco S et al. A Phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann. Oncol.19, 1068–1074 (2008).
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gomez HL, Aziz Z et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol.26, 5544–5552 (2008).
   PubMed Web of Science ®Google Scholar
• Toi M, Iwata H, Fujiwara Y et al. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients Phase II studies. Br. J. Cancer101, 1676–1682 (2009).
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355, 2733–2743 (2006).
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M et al. A Phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat.112, 533–543 (2008).
   PubMed Web of Science ®Google Scholar
• Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol.27, 5538–5546 (2009).
   PubMed Web of Science ®Google Scholar
• Gril B, Palmieri D, Bronder JL et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl Cancer Inst.100, 1092–1103 (2008).
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer9, 463–475 (2009).
   PubMed Web of Science ®Google Scholar
• Sutherland S, Ashley S, Miles D et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience. Br. J. Cancer102, 995–1002 (2010).
   PubMed Web of Science ®Google Scholar
• Blackwell K, Burstein H, Sledge G et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Presented at: San Antonio Breast Cancer Symposium. 10–13 December 2009 (Abstract supplement 12–15–2009).
   Google Scholar
• Tomasello G, de Azambuja E, Dinh P, Snoj N, Piccart-Gebhart M. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev. Anticancer Ther.8, 1883–1890 (2008).
   PubMed Web of Science ®Google Scholar
• Kaklamani V, Uthe R, Khan S et al. Pilot neoadjuvant trial with combination of lapatinib and nab-paclitaxel in HER2+ breast cancer. Cancer Res.69, 1091 (2009).
   Google Scholar
• Migliaccio I, Gutierrez MC, Wu M-F et al. PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC)#34. Cancer Res.69(Suppl. 2), 72S (2009).
   Google Scholar
• Guarneri V, Frassoldati A, Piacentini F et al. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial). Clin. Breast Cancer8, 192–194 (2008).
   PubMed Web of Science ®Google Scholar
• Guarneri V, Frassoldati A, Cagossi A et al. CHER LOB trial: preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer – safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data. J. Clin.Oncol.26, 26s (2008).
   PubMedGoogle Scholar
• Capri G, Chang J, Chen SC et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann. Oncol.21, 474–480 (2010).
   PubMed Web of Science ®Google Scholar
• Moy B, Rappold E, Williams L et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol.27(15S), 51S (2009).
   Google Scholar
• Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc.83, 679–686 (2008).
   PubMed Web of Science ®Google Scholar
• Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist12, 756–765 (2007).
   PubMed Web of Science ®Google Scholar
• O’Brien BE, Kaklamani VG, Benson AB III. The assessment and management of cancer treatment-related diarrhea. Clin. Colorectal Cancer4, 375–381 (2005).
   PubMedGoogle Scholar
• Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin. Exp. Dermatol.32, 71–74 (2007).
   PubMed Web of Science ®Google Scholar
• Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol.28, 1138–1144 (2010).
   PubMed Web of Science ®Google Scholar
• Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol.28, 2698–2704 (2010).
   PubMed Web of Science ®Google Scholar
• Lin NU, Diéras V, Paul D et al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res.15(4), 1452–1459 (2009).
   PubMed Web of Science ®Google Scholar